Phenotypic Detection of Common Resistance Patterns

Phenotypic detection of resistance patterns uses growth-based and biochemical tests to recognize specific, clinically important resistance mechanisms expressed by an organism, beyond simply categorizing it as susceptible or resistant. Classic examples include detecting extended-spectrum beta-lactamases (ESBLs), carbapenemases, and methicillin resistance in staphylococci.

Definition

Phenotypic resistance detection is the use of growth-based, synergy, or biochemical assays to demonstrate that an organism expresses a particular resistance mechanism, such as production of a specific beta-lactamase or carbapenemase, distinguishing the mechanism rather than only the susceptibility category.

Scope

This entry covers the principal phenotypic strategies for confirming common resistance patterns: combination-disk and double-disk synergy tests for ESBLs, biochemical and growth-based carbapenemase tests such as the Carba NP and carbapenem inactivation methods, and cefoxitin-based screening for methicillin resistance. It explains what these tests demonstrate and their limits, and is reference material rather than treatment guidance.

Core questions

• Does this organism express a specific resistance mechanism such as an ESBL or carbapenemase?
• Which phenotypic tests can confirm that mechanism, and what do their results mean?
• What are the limitations of phenotypic detection compared with molecular confirmation?

Key concepts

• Extended-spectrum beta-lactamase (ESBL) detection
• Double-disk synergy and combination-disk tests
• Carbapenemase detection (Carba NP, carbapenem inactivation method)
• Cefoxitin screening for methicillin resistance
• Inducible clindamycin resistance (D-test)
• Confirmatory versus screening tests
• Phenotype-genotype discordance

Mechanisms

Phenotypic tests reveal a resistance mechanism through its functional effect. ESBL detection relies on the restoration of susceptibility to an indicator cephalosporin when a beta-lactamase inhibitor (such as clavulanic acid) is added, seen as synergy in double-disk or combination-disk formats (paterson-2005). Carbapenemase activity can be detected biochemically by hydrolysis of a carbapenem, as in the Carba NP colorimetric test, or by growth-based assays such as the carbapenem inactivation method, in which a carbapenem disk exposed to the test organism loses its ability to inhibit a susceptible indicator strain (van-der-zwaluw-2015; nordmann-2009). Methicillin resistance in staphylococci is screened phenotypically using cefoxitin, a surrogate that better induces and detects mecA-mediated resistance, and inducible macrolide-lincosamide resistance is shown by the D-test. Expert rules help interpret these patterns and flag inconsistent results (leclercq-2013; clsi-m100).

Clinical relevance

Recognizing resistance phenotypes such as ESBL or carbapenemase production is central to infection control, surveillance, and stewardship, because these mechanisms affect whole classes of agents. This entry describes how such phenotypes are demonstrated in the laboratory as reference knowledge and does not provide individual diagnostic or prescribing guidance.

Epidemiology

Carbapenemase-producing Enterobacterales and ESBL producers have spread internationally, making their phenotypic detection a priority for laboratories and surveillance networks; the epidemiology of these mechanisms has shaped the development and adoption of confirmatory tests (nordmann-2009; paterson-2005).

History

As beta-lactam resistance mechanisms diversified from the 1980s onward, laboratories developed phenotypic confirmatory tests, beginning with inhibitor-based ESBL detection. The international emergence of carbapenemase-producing organisms in the 2000s prompted rapid biochemical and growth-based carbapenemase assays such as the Carba NP test and, later, the simpler carbapenem inactivation method (paterson-2005; nordmann-2009; van-der-zwaluw-2015).

Debates

Phenotypic versus molecular confirmation

Phenotypic tests detect functional activity but may not identify the specific gene, while molecular tests identify genes that are not always expressed; the appropriate combination and sequence of methods for confirming mechanisms such as carbapenemase production is debated.

Sensitivity for weakly expressed mechanisms

Some resistance mechanisms are expressed at low levels or only under induction, so phenotypic screening can miss them, raising questions about which confirmatory strategy provides adequate sensitivity.

Seminal works

• paterson-2005
• nordmann-2009
• van-der-zwaluw-2015

Frequently asked questions

What does an ESBL confirmatory test show?

It demonstrates that adding a beta-lactamase inhibitor restores the organism's susceptibility to an indicator cephalosporin, indicating production of an extended-spectrum beta-lactamase; it shows the functional mechanism rather than naming the specific enzyme.

Why detect carbapenemases phenotypically when molecular tests exist?

Phenotypic tests such as the carbapenem inactivation method are inexpensive and detect functional carbapenem-hydrolysing activity regardless of the specific gene, complementing molecular tests that target known genes but may miss novel ones.